Rapid recognition of microorganisms in the clinical microbiology laboratory can be valuable in clinical samples, enabling expedient de-escalation from broad-spectrum agents to casted antimicrobial therapy.
Fremont, CA: New technologies are emerging rapidly, and laboratory methods are being revolutionized; accurately, the ones most critical of any infections are characterized in clinical microbiology. The switch to tailored therapy reduces risks of antibiotics, namely, disruption of normal flora, toxic side effects, and selective pressure. Therefore, there is a primary need for new technologies in clinical microbiology, especially for bloodstream infections, in which the associated mortality rate is among the highest. Similarly, there is a need for the clinical laboratory community to adopt the practices of evidence-based interventional laboratory medicine and participate in translational research projects to establish the clinical utility, cost-benefit, and impact of new technologies.
Rapid identification of bloodstream infections (BSIs) and the associated condition called sepsis syndrome are of prime importance because of associated morbidity and mortality. It ranks among the most common causes of death in the United States alone, where over 600 patients die each day. Additionally, the incidence of BSI is said to increase by 10 percent annually in the upcoming years. According to the studies, the risk of death from septic shock increases by more than 7 percent, with every passing hour from the onset of shock until the start of targeted therapy. Therefore studies have confirmed that rapid identification of pathogens will benefit and also increase the chances of survival.
When laboratory methods rely entirely on the cultivation of pathogens and traditional phenotypic methods of pathogen characterization, the physicians are forced to study the presence of BSI on the basis of clinical symptoms, which are often nonspecific. There is an urgent, demanding need for new technologies in microbiology to bypass the issue of lag time for reports from positive blood cultures and other cultures. Many technological advances using simple molecular methods have become accessible in recent years and show potential for cost-benefit.